CN100533120C - Multiple colour fluorescent composite amplification kit for 11 pulmonary cancers susceptibility related SNP sites - Google Patents

Multiple colour fluorescent composite amplification kit for 11 pulmonary cancers susceptibility related SNP sites Download PDF

Info

Publication number
CN100533120C
CN100533120C CNB2007101127724A CN200710112772A CN100533120C CN 100533120 C CN100533120 C CN 100533120C CN B2007101127724 A CNB2007101127724 A CN B2007101127724A CN 200710112772 A CN200710112772 A CN 200710112772A CN 100533120 C CN100533120 C CN 100533120C
Authority
CN
China
Prior art keywords
site
primer
allelic
auele specific
specific primer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2007101127724A
Other languages
Chinese (zh)
Other versions
CN101158633A (en
Inventor
王瑞恒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liaoning Normal University
Original Assignee
Liaoning Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liaoning Normal University filed Critical Liaoning Normal University
Priority to CNB2007101127724A priority Critical patent/CN100533120C/en
Publication of CN101158633A publication Critical patent/CN101158633A/en
Application granted granted Critical
Publication of CN100533120C publication Critical patent/CN100533120C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Abstract

The invention relates to a disposable multicolor fluorescence combined augmentation reagent kit for 11 SNP gene loci which are related to lung cancer/munity for extracorporeal use, comprising separately packed primer mixture, DNA polymerase, buffer solution, quality control DNA specimen and allele parting normal mixture. Wherein, the primer mixture consists of 11 sharing primers marked by fluorescence and 22 length specificity primers specific to different alleles, the invention particularly consists of 2.0ml of primer mixture (therein gene locus has different primer consistency, 30nM-240nM), 1000u of DNA polymerase, 2.0ml of buffer solution, 1ml of the total amount of allele parting normal mixture, and 0.1ml (10ng/ul) of quality control DNA. Under the condition of best primer mixture ratio, the invention can rapidly and accurately obtain the genotypes of the 11 SNP points related to the lung cancer munity.

Description

A multiple colour fluorescent composite amplification 11 lung cancer susceptibility related SNP site kit
Technical field
The present invention relates to a kind of kit that is used for 11 SNP locus that lung cancer susceptibility is relevant on the external disposable composite amplification chromosome, belong to the invention of lung cancer susceptibility detection range.
Background technology
Along with finishing of the accurate sequence chart of the Human Genome Project (Human Genome Project), the clone of functional gene and evaluation, the multifarious research of human genome have become next scientific and technological commanding elevation.Restriction fragment length polymorphism (restriction fragment length polymorphism RFLP) and microsatellite polymorphism (microsatellite polymorphisms) be as the first generation and second generation genetic marker, takes at the splicing of the structure of physical map and genetic map, sequence base figure and dress and once played conclusive effect in the process.
The E.Lander of the U.S. in 1996 propose first to be referred to as " third generation genetic marker " " single nucleotide polymorphism " (single nucleotide polymorphism, SNP).SNP is meant the dna sequence polymorphism that the variation of single nucleotide on chromogene group level causes, and the wherein minimum frequency of a kind of allele in colony is not less than 1%.It comprises the forms such as conversion, transversion, insertion and disappearance of single base.SNP has following characteristics: at first, the SNP site is very abundant.Almost be distributed in whole genome, 1 SNP will appear in about average every 1000bp in the genome, and sum has 3,000,000 approximately.Secondly, the mutation rate of SNP is lower, and per generation, every base mutation rate was about 2 * 10 -8Especially being in (coding region) SNP (claiming cSNP again) of code area, is high stability, and the feasible genetic analysis to colony of the high mutation rate of the microsatellite locus that series connection repeats encounters difficulties.The 3rd, representative.CSNP often causes the polymorphic variation of expressing protein, and and then influences their function, characteristic.The 4th, the amplification segment is short, is easy to meet amplification, easily realizes the robotization of analyzing.
At present, the research work of human genome enters the genome times afterwards comprehensively (Post genome Era), researchist's emphasis is in the functional genomics field, comprising disease gene evaluation, gene expression adjusting, human diversity and every research work such as evolution, protein structure and function.In this case, as a genoid research tool, SNP is widely used in the research of aspects such as genetic disease, human evolution, biotic population diversity.
The research of SNP and various diseases relation more and more is subjected to researchist's attention.If draw particular combinations and specified disease, the particular locality morbidity crowd of some SNP or some SNP obvious correlativity is arranged, just can be with this SNP as molecular genetic marker, carry out the prevention of molecular marker assisted selection and disease forecasting, in epidemiology survey, determine disease patient's people at highest risk, and the evaluation of carrying out ill hazard level, set up effective early warning system, reach effective primary prevention purpose.
Studies show that in recent years, have strong correlation between many tumor susceptibilities and the SNP, such as: the Lys allele of the T allele of the Met/Met genotype of XRCC3 (Thr241Met), LIG4 (T1977C), the C allele of RAD51 (G135C), XPD (Lys751G1n) increases individual prostate cancer, breast cancer, SCCHN, the risk for lung cancer suffered from respectively.Carry the easier trouble tumour of individuality of this kind genotype or haplotype.The T allele of GSTM4 (T2517C) increases the individual possibility of suffering from lung cancer, and the CC genotype of NQO1 (C609T ') increases the individual risk for lung cancer of suffering from, and the GG genotype of hOGG1 (A11656G) increases the neurological susceptibility of lung cancer; LIG4 Ile658Val, Tp53 Arg72Pro, PLOI (RAD3OB) Thr706Ala, REV1 Phe257Ser SNP suddenly change all relevant with lung cancer susceptibility; AXIN2Pro50Ser, XPD Lys751Gln, XPC Lys939Gln, MPO-463G-〉SNP sudden changes such as A, XRCC1 194Trp/Arg, MBD4Glu346Lys, LRMPV141L, RASSF1 Alal33Ser, CYP1B1 Val432Leu, ADPRTVal762Ala all increase the neurological susceptibility of lung cancer.These specific markers can be used as the molecular labeling of judging individual certain tumor susceptibility, carry out disease forecasting, thereby can determine to suffer from the people at highest risk of certain tumour.
The research of SNP locus mostly one by one the site carry out, detection means or just use sequencing technologies perhaps adopts order-checking or adopts the method for digestion with restriction enzyme, the former technical sophistication, expense costliness; Latter's complex operation, poor accuracy.Composite amplification (Multiplex PCR) is called multiplex PCR again, promptly uses many cover primers in a reaction system, the process that increases at the zones of different of a plurality of dna profilings or same template.It can simplify procedures significantly, save time and reagent, can satisfy the needs of analyzing the different genes site simultaneously simultaneously.
Based on the difference of detection architecture, in the world composite amplification mainly can be divided into two big classes at present: cma staining composite amplification and fluorescent composite amplification.The former is that the common electrophoresis tank of the product utilization behind the composite amplification separates, and carries out the method that cma staining detects, and method is simple, and cost is lower, can carry out this project in common lab.But because the just single color of planting of gained result, so the number of sites of its composite amplification reagent kit can not be too many, the site of general 1 composite amplification can not surpass 4, otherwise can be difficult to distinguish the genotype of sample because the amplified production of different loci overlaps each other.Add the gained result and detect by an unaided eye, so its sensitivity is subjected to certain restriction.
Fluorescent composite amplification is that wherein primer one end at common composite amplification PCR adds fluorescence labeling, utilizes automatic laser fluorescence Genetic Detection instrument to detect pcr amplification product, and the result is accurate, highly sensitive, automaticity is high, repeatability is strong etc.With fluorescein-labelled one group of 3 or 4 gene loci of a kind of color (its amplified fragments can not overlaid), 3 or 4 gene locis of fluorescein-labelled another group of another kind of color, multiple fluorescein then can the different gene locis of the many groups of mark.Automatic laser fluorescence Genetic Detection instrument can detect tens kinds of fluoresceins at present, but in a reaction system, can detect 5 kinds of fluoresceins simultaneously at most, except that wherein a kind of as the interior mark, all the other four kinds of fluoresceins can be used for marked product, add together, just can reach the purpose of the gene loci of 1 detection more than 10.
Fluorescent composite amplification has become present advanced person's composite amplification method.
Summary of the invention
The present invention has screened 11 through studies have shown that the SNP locus relevant with lung cancer susceptibility, and according to the principle of primer specificity PCR, each SNP locus has designed 3 primers.In each SNP locus side 100-280bp scope, designed a primer,, and selected a kind of fluorescent material mark for use at primer 5 ' end as the shared primer of this locus; Not iso-allele at the SNP locus, designed again respectively and SNP locus two primers being complementary of iso-allele not, as Auele Specific Primer, primer 3 ' last terminal base is mated with the not homoallelic base of SNP locus respectively, but can not suppression of amplification owing to have only 3 ' last terminal base often not match, so in order to prevent the mistake amplification, base mismatch of the artificial introducing of 3 ' terminal the 3rd or 4 bit bases, this is the most key part of design of primers; At last for the different allele of automatic distinguishing when detecting, two primer lengths differ 4bp (if two primer Tm values have big difference during the design primer, then artificially introduce four bases of TATA, this is another key of primer difference design, because TATA is minimum to the annealing temperature influence of primer, satisfied simultaneously the different requirement of amplification fragment length again), all primer length 18-28bp, for the ease of composite amplification, the Tm value of all primers remains on 60 ± 0.5 ℃, for the competition that reduces between the primer suppresses, primer concentration to different SNP site in the reaction system is adjusted, obtain best primer concentration proportioning, prevented the generation of non-specific amplification segment.Utilize this kit, just can carry out composite amplification to 11 relevant SNP locus of lung cancer susceptibility simultaneously easily, obtain the genotype result of each locus; Simultaneously, the allelic ladder that utilizes this kit to provide utilizes genetic analysis software (Genetyper2.5.2), can also detect automatically easily, analysing amplified result.
Description of drawings
Fig. 1 is the structural formula of blue-fluorescence label 6-FAM.
Fig. 2 is the structural formula of yellow fluorescence label 6-TAMRA (Tetramethyl-rhodamine).
Fig. 3 be green fluorescence label JOE (6-carboxy-4 ', 5 '-dichloro-2 ', 7 '-dimethoxy-fluorescein) structural formula.
Fig. 4 is the structural formula of red fluorescence label 6-ROX (X-RHODAMINE).
Embodiment
This kit is to be made of 11 SNP site primer mixtures that separate packing, archaeal dna polymerase, reaction buffer (containing MgCl2) and 11 SNP site allelic ladders and Quality Control DNA.The primer mixture 2.0ml of 11 SNP locus (different genes seat primer concentration is inequality, and from 30nM-240nM, consumption is 2ul in the composite PCR reaction system of each 20ul); Archaeal dna polymerase 1000u (consumption is 1u in the composite PCR reaction system of each 20ul of 5u/p1); Damping fluid 2.0ml (10 times of concentrated damping fluids, consumption is 2ul in the composite PCR reaction system of each 20ul); Allelic ladder amount of the mixture 1ml (40nM detects use for 1000 times), the allelic ladder equivalent of contained each locus in the allelic ladder potpourri; Quality Control DNA0.1ml (10ng/ul).
The technological core of fluorescent composite amplification mainly is the concentration proportioning of primer sequence and fluorescently-labeled position and various primers.In kit of the present invention, 11 SNP sites are there are some researches show and the closely-related locus of lung cancer susceptibility that its reference sequences all can be consulted by NCBI, and the register in 11 SNP sites is:
Figure C200710112772D0008082725QIETU
, ,
Figure C200710112772D0008082750QIETU
,
Figure C200710112772D0008082820QIETU
,
Figure C200710112772D0008082827QIETU
,
Figure C200710112772D0008082832QIETU
,
Figure C200710112772D0008082837QIETU
,
Figure C200710112772D0008082842QIETU
,
Figure C200710112772D0008082857QIETU
,
Figure C200710112772D0008082909QIETU
,
Figure C200710112772D0008082916QIETU
11 lung cancer susceptibility related SNP site primer sequences are:
RASSF1-pub-5 '-F1-GAAGCCCTGGGTTCCTCAA-3 ' (primer is shared in the RASSF1 site, and F1 is fluorescein-labelled)
RASSF1-spel-5 '-GATCTTCTGCTCAATCTCGGC-3 ' (RASSF1 locus specificity primer 1 is at C allele)
RASSF1-spe2-5 '-TATAGATCTTCTGCTCAATCTCGGA-3 ' (RASSF1 locus specificity primer 2 is at A allele)
MBD4-pub-5 '-F1-TTTCCTGGTTGGTGAGCAGTT-3 ' (primer is shared in the MBD4 site, and F1 is fluorescein-labelled)
MBD4-spe1-5 '-GCCAAAGACTCAGAACACACCA-3 ' (MBD4 locus specificity primer 1 is at A allele)
MBD4-spe2-5 '-TATATCCAAAGACTCAGAACACATCG-3 ' (MBD4 locus specificity primer 2 is at G allele)
XPD-pub-5 '-F1-CGGACATCTCCAAATTCATTCA-3 ' (primer is shared in the XPD site, and F1 is fluorescein-labelled)
XPD-spe1-5 '-CTGAGCAATCTGCTCTATCCTGTT-3 ' (XPD locus specificity primer 1 is at T allele)
XPD-spe2-5 '-TATACTGAGCAATCTGCTCTATCCTATG-3 ' (XPD locus specificity primer 2 is at G allele)
XRCC1-pub-5 '-F1-TCCAGACAAAGATGAGGCAGAG-3 ' (primer is shared in the XRCC1 site, and F1 is fluorescein-labelled)
XRCC1-spel-5 '-CTGGGGATGTCTTGTTGAACC-3 ' (XRCC1 locus specificity primer 1 is at G allele)
XRCC1-spe2-5 '-TATATTGGGGATGTCTTGTTGAGCT-3 ' (XRCC1 locus specificity primer 2 is at A allele)
ADPRT-pub-5 '-F2-CAGCAGGAGGGTTTGCCA-3 ' (primer is shared in the ADPRT site, and F2 is fluorescein-labelled)
ADPRT-spel-5 '-AGCAGGTTGTCAAGCATTTACG-3 ' (ADPRT locus specificity primer 1 is at C allele)
ADPRT-spe2-5 '-TATAAGCAGGTTGTCAAGCATTTACA-3 ' (ADPRT locus specificity primer 2 is at T allele)
CYP1B1-pub-5 '-F2-GAGGGACCGTCTGCCTTGTA-3 ' (primer is shared in the CYP1B1 site, and F2 is fluorescein-labelled)
CYP1B1-sepl-5 '-CCGGGTTAGGCCACTTGAG-3 ' (CYP1B1 locus specificity primer 1 is at C allele)
CYP1B1-sep2-5 '-TATACCGGGTTAGGCCACTTTAC-3 ' (CYP1B1 locus specificity primer 2 is at G allele)
REV1-pub-5 '-F2-AGTCAATGGCATGAACAGTTGG-3 ' (primer is shared in the REV1 site, and F2 is fluorescein-labelled)
REV1-spel-5 '-CCTTATCCTCCTCCTGGGAAA-3 ' (REV1 locus specificity primer 1 is at T allele)
REV1-spe2-5 '-TATACCTTATCCTCCTCCTGGGTAG-3 ' (REV1 locus specificity primer 2 is at C allele)
XPC-pub-5 '-F2-TGATTACTAACCCTCGCCTGTG-3 ' (primer is shared in the XPC site, and F2 is fluorescein-labelled)
XPC-spel-5 '-GGCGCTCAGCTCACAGGTT-3 ' (XPC locus specificity primer 1 is at A allele)
XPC-spe2-5 '-TATAAGCGCTCAGCTCACAGTTG-3 ' (XPC locus specificity primer 2 is at C allele)
GSTM4-pub-5 '-F3-GGAAAGGCGTCCAAGCAGT-3 ' (primer is shared in the GSTM4 site, and F3 is fluorescein-labelled)
GSTM4-sepl-5 '-GGCCATGGTTTGTTGGACAC-3 ' (GSTM4 locus specificity primer 1 is at C allele)
GSTM4-sep2-5 '-TATAGGCCATGGTTTGTTGGATAT-3 ' (GSTM4 locus specificity primer 2 is at T allele)
AXIN2-pub-5 '-F4-CAGCAGCAGCTTCCGTGAG-3 ' (primer is shared in the AXIN2 site, and F4 is fluorescein-labelled)
AXIN2-spel-5 '-CCTGGTGTTGGAAGAGACTGG-3 ' (AXIN2 locus specificity primer 1 is at C allele)
AXIN2-spe2-5 ' TATACCTGGTGTTGGAAGAGACCGA-3 ' (AXIN2 locus specificity primer 2 is at T allele)
PLOI-pub-5 '-F4-CAGATAGCCATAAGCAAACAGTAGC-3 ' (primer is shared in the PLOI site, and F4 is fluorescein-labelled)
PLOI-spel-5 '-ATGTGGAAATCTGATCCGGC-3 ' (PLOI locus specificity primer 1 is at G allele)
PLOI-spe2-5 '-TATAATGTGGAAATCTGATCCGGT-3 ' (PLOI locus specificity primer 2 is at A allele)
The title and the structure of four kinds of fluoresceins are respectively:
F1: blue-fluorescence label 6-FAM, structural formula are Fig. 1.
F2: yellow fluorescence label 6-TAMRA (Tetramethyl-rhodamine), structural formula are Fig. 2.
F3: green fluorescence label JOE (6-carboxy-4 ', 5 '-dichloro-2 ', 7 '-dimethoxy-fluorescein), structural formula is Fig. 3.
F4: red fluorescence label 6-ROX (X-RHODAMINE), structural formula are Fig. 4.
Need to prove that four kinds of fluorescent markers can exchange.
Above-mentioned primer design is very crucial, and its design needs to consider the key element of the following aspects: (1), all sites obtain amplification simultaneously, and promptly the right annealing temperature of all primers must be close; (2) do not form primer dimer between the primer; (3), do not form secondary structure.
All primers that comprised above-mentioned 11 SNP locus in the kit of the present invention, 3 primers in each site, wherein one is to share with primer, use different fluorescein-labelled respectively, the two other primer is at different SNP allele designs, match the different allele of amplification respectively with shared primer, because primer length difference, so different amplified allele product length difference, generally differ 4bp, detect, just can distinguish different allele according to the difference of product length by automatic laser fluorescence Genetic Detection instrument, if homozygote can only obtain 1 product peak; And if heterozygote then can obtain two product peaks.
For the allelic detection of SNP, the most direct method the most accurately is a gene sequencing, but this method is carried out in the site inefficiency, technical requirement height and expense costliness one by one; Secondly method commonly used is the allele according to the SNP site, seek the restriction enzyme that is fit to, difference according to digestion with restriction enzyme afterproduct length, distinguish different allele, but this method also one by one site SNP detect, and not exclusively derive a wrong conclusion owing to the digestion of enzyme sometimes, so have the shortcoming of inefficiency, poor accuracy.This method detects the amplification simultaneously in a reaction tube of 11 SNP sites simultaneously, and efficient improves greatly, and (GenoTyper2.5.2) can analyze the result automatically in conjunction with genetic analysis software, can finish the detection of routine samples up to a hundred in one day; Because fluoroscopic examination has high sensitivity,, once only need 5-10ng so detect extremely trace of needed sample size; Not homoallelic amplified production length differs 4bp, can satisfy the requirement that detects fully; By the debugging primer concentration, obtained best primer concentration proportioning, can effectively suppress the appearance of non-specific amplification product; The SNP site of selecting in this kit is position lung cancer susceptibility related gene site all, can play a significant role in the prediction of lung cancer susceptible risk, reaches the purpose of primary prevention.
When carrying out the composite amplification reaction, can in the PCR reaction system, add the four kinds of required deoxynucleoside triphosphates of primer mixture, archaeal dna polymerase, damping fluid and popular response that separate packing in this kit simultaneously, just can carry out pcr amplification effectively.Concrete reaction system is as follows:
Sample DNA (5-10ng) 1ul
Primer mixture 2ul
dNTPs 1.6ul
Damping fluid 2ul
Archaeal dna polymerase 0.2ul (1u)
Aseptic deionized water is supplemented to 20ul
The Quality Control DNA sample and 11 the SNP site allelic ladders (Ladder) that are used for standard different experiments chamber assay also are provided in the kit of the present invention, Quality Control DNA sample be through order-checking proved conclusively according to the accurate DNA sample of somatotype of the operation instructions of this kit, can be used as the use of positive control or standard DNA sample; Allelic ladder is that the inventor has collected all allelic amplified productions of 11 SNP sites, use as standard when being used for genetic analysis software automatic parting direction, adopt this allelic ladder, can be fast, accurately testing result is carried out somatotype; Simultaneously as long as with allelic ladder and the synchronous electrophoresis of sample pcr amplification product, different laboratories, different equipment, different electrophoresis methods, all can obtain consistent repeatable result, can be used for the testing result of standard different experiments chamber, avoid the error that causes because of electrophoresis.
Kit of the present invention can carry out composite amplification to the relevant SNP locus of 11 lung cancer susceptibilities expeditiously, detect somatotype by automatic fluorescence sequenator, reach the high automation level, the purpose that experimental result is accurate, reproducibility is good, kit of the present invention are used for the lung cancer prediction and the risk evaluation has very big advantage and potentiality.

Claims (1)

1, a kind of 11 SNP sites multiple colour fluorescent composite amplification reagent kits, this kit comprises a) primer mixture, b) archaeal dna polymerase c) contains MgCl 2Damping fluid, d) Quality Control DNA, e) allelic ladder potpourri, primer mixture is shared primer and 22 by 11 fluorescence labelings and is formed at not homoallelic length Auele Specific Primer, respectively at 11 lung cancer related SNP gene locis, be respectively RASSF1 (Ala133Ser), MBD4 (Glu346Lys), XPD (Lys751Gln), XRCC1 (194Trp/Arg), ADPRT (Val762Ala), CYP1B1 (Val432Leu), REV1 (Phe257Ser), XPC (Lys939Gln), GSTM4 (T2517C), AXIN2 (Pro50Ser), PLOI (Thr706Ala), 11 SNP gene loci primer sequences are: RASSF1-pub-5 '-F1-GAAGCCCTGGGTTCCTCAA-3 ', primer is shared in the RASSF1 site, RASSF1-spe1-5 '-GATCTTCTGCTCAATCTCGGC-3 ', the RASSF1 site is at the allelic Auele Specific Primer of C, RASSF1-spe2-5 '-TATAGATCTTCTGCTCAATCTCGGA-3 ', the RASSF1 site is at the allelic Auele Specific Primer of A, MBD4-pub-5 '-F1-TTTCCTGGTTGGTGAGCAGTT-3 ', primer, MBD4-spe1-5 '-GCCAAAGACTCAGAACACACCA-3 ' are shared in the MBD4 site, the MBD4 site is at the allelic Auele Specific Primer of A, MBD4-spe2-5 '-TATATCCAAAGACTCAGAACACATCG-3 ', the MBD4 site is at the allelic Auele Specific Primer of G, XPD-pub-5 '-F1-CGGACATCTCCAAATTCATTCA-3 ', primer is shared in the XPD site, XPD-spe1-5 '-CTGAGCAATCTGCTCTATCCTGTT-3 ', the XPD site is at the allelic Auele Specific Primer of T, XPD-spe2-5 '-TATACTGAGCAATCTGCTCTATCCTATG-3 ', the XPD site is at the allelic Auele Specific Primer of G, XRCC1-pub-5 '-F1-TCCAGACAAAGATGAGGCAGAG-3 ', primer, XRCC1-spe1-5 '-CTGGGGATGTCTTGTTGAACC-3 ' are shared in the XRCC1 site, the XRCC1 site is at the allelic Auele Specific Primer of G, XRCC1-spe2-5 '-TATATTGGGGATGTCTTGTTGAGCT-3 ', the XRCC1 site is at the allelic Auele Specific Primer of A, ADPRT-pub-5 '-F2-CAGCAGGAGGGTTTGCCA-3 ', primer is shared in the ADPRT site, ADPRT-spe1-5 '-AGCAGGTTGTCAAGCATTTACG-3 ', the ADPRT site is at the allelic Auele Specific Primer of C, ADPRT-spe2-5 '-TATAAGCAGGTTGTCAAGCATTTACA-3 ', the ADPRT site is at the allelic Auele Specific Primer of T, CYP1B1-pub-5 '-F2-GAGGGACCGTCTGCCTTGTA-3 ', primer, CYP1B1-sep1-5 '-CCGGGTTAGGCCACTTGAG-3 ' are shared in the CYP1B1 site, the CYP1B1 site is at the allelic Auele Specific Primer of C, CYP1B1-sep2-5 '-TATACCGGGTTAGGCCACTTTAC-3 ', the CYP1B1 site is at the allelic Auele Specific Primer of G, REV1-pub-5 '-F2-AGTCAATGGCATGAACAGTTGG-3 ', primer is shared in the REV1 site, REV1-spe1-5 '-CCTTATCCTCCTCCTGGGAAA-3 ', the REV1 site is at the allelic Auele Specific Primer of T, REV1-spe2-5 '-TATACCTTATCCTCCTCCTGGGTAG-3 ', the REV1 site is at the allelic Auele Specific Primer of C, XPC-pub-5 '-F2-TGATTACTAACCCTCGCCTGTG-3 ', primer, XPC-spe1-5 '-GGCGCTCAGCTCACAGGTT-3 ' are shared in the XPC site, the XPC site is at the allelic Auele Specific Primer of A, XPC-spe2-5 '-TATAAGCGCTCAGCTCACAGTTG-3 ', the XPC site is at the allelic Auele Specific Primer of C, GSTM4-pub-5 '-F3-GGAAAGGCGTCCAAGCAGT-3 ', primer is shared in the GSTM4 site, GSTM4-sep1-5 '-GGCCATGGTTTGTTGGACAC-3 ', the GSTM4 site is at the allelic Auele Specific Primer of C, GSTM4-sep2-5 '-TATAGGCCATGGTTTGTTGGATAT-3 ', the GSTM4 site is at the allelic Auele Specific Primer of T, AXIN2-pub-5 '-F4-CAGCAGCAGCTTCCGTGAG-3 ', primer, AXIN2-spe1-5 '-CCTGGTGTTGGAAGAGACTGG-3 ' are shared in the AXIN2 site, the AXIN2 site is at the allelic Auele Specific Primer of C, AXIN2-spe2-5 ' TATACCTGGTGTTGGAAGAGACCGA-3 ', the AXIN2 site is at the allelic Auele Specific Primer of T, PLOI-pub-5 '-F4-CAGATAGCCATAAGCAAACAGTAGC-3 ', primer is shared in the PLOI site, PLOI-spe1-5 '-ATGTGGAAATCTGATCCGGC-3 ', the PLOI site is at the allelic Auele Specific Primer of G, PLOI-spe2-5 '-TATAATGTGGAAATCTGATCCGGT-3 ', the PLOI site is at the allelic Auele Specific Primer of A, and the title of four kinds of fluoresceins is respectively: F1: blue-fluorescence label FAM; F2: yellow fluorescence label TAMRA; F3: green fluorescence label JOE; F4: red fluorescence label ROX; Four kinds of fluorescent markers can exchange.
CNB2007101127724A 2007-03-24 2007-06-17 Multiple colour fluorescent composite amplification kit for 11 pulmonary cancers susceptibility related SNP sites Expired - Fee Related CN100533120C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2007101127724A CN100533120C (en) 2007-03-24 2007-06-17 Multiple colour fluorescent composite amplification kit for 11 pulmonary cancers susceptibility related SNP sites

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200710010709.X 2007-03-24
CN200710010709 2007-03-24
CNB2007101127724A CN100533120C (en) 2007-03-24 2007-06-17 Multiple colour fluorescent composite amplification kit for 11 pulmonary cancers susceptibility related SNP sites

Publications (2)

Publication Number Publication Date
CN101158633A CN101158633A (en) 2008-04-09
CN100533120C true CN100533120C (en) 2009-08-26

Family

ID=39306794

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2007101127724A Expired - Fee Related CN100533120C (en) 2007-03-24 2007-06-17 Multiple colour fluorescent composite amplification kit for 11 pulmonary cancers susceptibility related SNP sites

Country Status (1)

Country Link
CN (1) CN100533120C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102040307B1 (en) * 2010-11-30 2019-11-27 더 차이니즈 유니버시티 오브 홍콩 Detection of genetic or molecular aberrations associated with cancer
CN102337281A (en) * 2011-10-17 2012-02-01 复旦大学 Molecular marker for predicting curative effect of platinum-based chemotherapy for ANSCLC (advanced non-small cell lung cancer) and application thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
An Evolutionary Perspective onSingle-NucleotidePolymorphism Screening in MolecularCancer Epidemiology. Yong Zhu, Margaret R. Spitz et al.Cancer Research,Vol.6 No.4. 2004
An Evolutionary Perspective onSingle-NucleotidePolymorphism Screening in MolecularCancer Epidemiology. Yong Zhu, Margaret R. Spitz et al.Cancer Research,Vol.6 No.4. 2004 *
Variants in the GH-IGF axis confer susceptibility to lungcancer. Matthew F.Rudd, Emily L. Webb et al.Genome Research,No.16. 2006
Variants in the GH-IGF axis confer susceptibility to lungcancer. Matthew F.Rudd, Emily L. Webb et al.Genome Research,No.16. 2006 *

Also Published As

Publication number Publication date
CN101158633A (en) 2008-04-09

Similar Documents

Publication Publication Date Title
CN106868150B (en) A kind of mankind's autosome and Y chromosome InDel genetic polymorphism site composite amplification reagent kit and its application
CN103451311B (en) The test kit of the fluorescence labeling composite amplification of analyst's genomic dna 26 locus and using method thereof and application while of a kind of
KR101171635B1 (en) Method of detecting variation and kit to be used therein
WO1995015400A1 (en) Genotyping by simultaneous analysis of multiple microsatellite loci
CN109486943A (en) For detecting and the primer sets of aspirin resistance related gene polymorphic site and kit and its application
CN104745691A (en) Primer group complexly amplified by fluorescent mark for synchronously analyzing 27 genetic locus of human genomic DNA, kit and application
CN105463116B (en) A kind of Forensic medicine composite detection kit and detection method based on 20 triallelic SNP genetic markers
CN106929591A (en) A kind of human HLA B*5801 genetic polymorphism detection kits
CN101622363B (en) Probe for detecting mutation in jak2 gene and use thereof
US9012619B2 (en) Probe for detecting ABL gene mutation and uses thereof
CN102321748A (en) Test kit and the method for use and the application of the fluorescence labeling composite amplification of 22 locus of a kind of while analyst genomic dna
CN106399479A (en) SNP typing kit used for detecting susceptibility genes of type-II diabetes
CN105385763A (en) Fluorescence labeled multiplex amplification kit for simultaneously analyzing 24 loci of human genome DNA, and application thereof
CN105256075B (en) The fluorescent PCR kit and detection method of eight kinds of Genotypings of hepatitis type B virus
WO2012099397A2 (en) Method for determining the single nucleotide polymorphism of target genes using a real-time polymerase chain reaction, and kit for determining the single nucleotide polymorphism of target genes using same
KR101358416B1 (en) Method for Detecting Target Genes or Their Mutations Using Ligase Reaction and Nicking Amplification Reaction
CN100543450C (en) 13 SNP sites multiple colour fluorescent composite amplification reagent kits that are used for individual identification
CN107586857B (en) Nucleic acid, kit and method for rapidly identifying red and black hair color genes of pigs
CN100533120C (en) Multiple colour fluorescent composite amplification kit for 11 pulmonary cancers susceptibility related SNP sites
CN109706248A (en) Forensic medicine composite detection kit and its application based on SNP-STR genetic marker
CN102399900B (en) Gene polymorphism detection method and kit
CN111996244A (en) Composition for detecting single nucleotide polymorphism and application thereof
CN104131101B (en) A kind of reagent and application thereof detecting P53 gene SNP site
CN103103267A (en) Kit for detecting genotype of human chromosome 21 STR (short tandem repeat)
KR20120124029A (en) Probe for detecting polymorphism, method of detecting polymorphism, method of evaluating drug efficacy and reagent kit for detecting polymorphism

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090826

Termination date: 20110617